Sun Pharma receives Australian TGA approval for Winlevi to treat acne vulgaris in patients 12 years of age and older
Overview
Sun Pharmaceutical Industries Limited announced that the Australian Therapeutic Goods Administration (TGA) has granted regulatory approval for Winlevi (clascoterone cream 1%). Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
Words from Sun Pharma Leaders
- As stated by Hellen de Kloet, business head – Western Europe, Australia and New Zealand, Sun Pharma “Winlevi is an exciting addition to our expanding dermatology portfolio of innovative medicines in Australia. Winlevi’s novel mechanism of action will be a welcome addition to the physician’s toolkit while treating acne.”
- Diana Harbort, president of the dermatology division of Cosmo, said: “We are very pleased that Winlevi will soon be available to patients in Australia. This is another achievement in the mission of Cosmo and Sun Pharma to improve the lives of patients affected by skin conditions.”
Availability- According to a company press release, Winlevi will be available in Australia by this June.
Indication and Mechanism
- Winlevi is approved for the topical treatment of acne vulgaris in people 12 years of age and older.
- Although the exact mechanism of action for Winlevi is unknown, laboratory studies suggest the active ingredient, clascoterone, competes with androgens, specifically dihydrotestosterone (DHT), for binding to the androgen receptors within the sebaceous gland and hair follicles.
About Androgens
- Androgens are widely recognized as the most important of all hormones in terms of regulating sebum production.
- Within the skin, androgens bind to androgen receptors, causing increased sebum production and inflammation.
- In particular, the skin of patients with acne vulgaris produces higher levels of the androgens testosterone and dihydrotestosterone (DHT) than the skin of healthy individuals.
Winlevi: MOA
- Winlevi binds to the androgen receptor competing with androgens such as DHT on cells within the sebaceous gland.
- Although its precise mechanism of action is unknown, studies suggest Winlevi inhibits androgen receptors5 in the skin and reduces production of sebum and inflammation.
- Additionally, Winlevi is rapidly metabolized in the skin, limiting systemic absorption.
Other Exclusive Rights
Sun Pharma has received from Cosmo the exclusive right to develop and commercialize Winlevi in US, Japan, Australia, New Zealand, Brazil, Mexico and Russia.
About Sun Pharma
- Sun Pharma is the world’s fourth largest specialty generics company with presence in specialty, generics and consumer healthcare products.
- It is the largest pharmaceutical company in India, and is a leading generic company in the US as well as global emerging markets.
